JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

1/11/23 1:00:00 PM ET

$AEZS

$AIM

$AMAO

$AREC

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AEZS alert in real time by email

- Live video webcast presentations with participating companies -

FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. As part of the virtual event, participating companies will provide a corporate presentation.

The schedule for the event is as follows:

Tuesday, January 17, 2023

9:00 AM ET: Moleculin Biotech, Inc. (NASDAQ:MBRX) - WEBCAST
10:00 AM ET: Xenetic Biosciences, Inc. (NASDAQ:XBIO) - WEBCAST
11:00 AM ET: Outlook Therapeutics, Inc. (NASDAQ:OTLK) - WEBCAST
1:00 PM ET: Vallon Pharmaceuticals, Inc. (NASDAQ:VLON)/GRI Bio (Private) - WEBCAST
2:00 PM ET: Novan, Inc. (NASDAQ:NOVN) - WEBCAST
3:00 PM ET: Palisade Bio, Inc. (NASDAQ:PALI) - WEBCAST
4:00 PM ET: American Resources Corporation (NASDAQ:AREC) - WEBCAST

Wednesday, January 18, 2023

10:00 AM ET: CNS Pharmaceuticals Inc. (NASDAQ:CNSP) - WEBCAST
11:00 AM ET:AIM ImmunoTech Inc. (NYSE:AIM) - WEBCAST
1:00 PM ET: Panavance Therapeutics Inc. (Private) - WEBCAST
2:00 PM ET: ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) -WEBCAST
3:00 PM ET: Ceapro, Inc. (TSXV:CZO, OTCQX:CRPOF) - WEBCAST
4:00 PM ET: iTolerance, Inc. (Private) - WEBCAST

Thursday, January 19, 2023

10:00 AM ET: Adolore Biotherapeutics, Inc. (Private) - WEBCAST
11:00 AM ET: Cyclo Therapeutics, Inc. (NASDAQ:CYTH) - WEBCAST
1:00 PM ET: enVVeno Medical Corporation (NASDAQ:NVNO) - WEBCAST
2:00 PM ET: American Acquisition Opportunity Inc. (NASDAQ:AMAO) - WEBCAST
3:00 PM ET: Aeterna Zentaris Inc. (NASDAQ:AEZS, TSX:AEZS) - WEBCAST
4:00 PM ET: SurgePays, Inc. (NASDAQ:SURG) - WEBCAST

About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

Contact:

Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
[email protected]

SOURCE: JTC Team, LLC

View source version on accesswire.com:
https://www.accesswire.com/734876/JTC-Team-to-Host-the-Virtual-Investor-2023-Companies-to-Watch-Event-on-January-17th-18th-and-19th

Get the next $AEZS alert in real time by email

Company	Date	Price Target	Rating	Analyst
Outlook Therapeutics Inc. $OTLK	3/27/2024	$50.00	Neutral → Buy	BTIG Research
SurgePays Inc. $SURG	3/13/2024		Buy → Hold	Maxim Group
Outlook Therapeutics Inc. $OTLK	2/15/2024	$3.00	Neutral → Buy	Chardan Capital Markets
Outlook Therapeutics Inc. $OTLK	1/25/2024		Neutral → Buy	Guggenheim
Outlook Therapeutics Inc. $OTLK	12/27/2023	$5.00	Equal Weight → Overweight	CapitalOne
Outlook Therapeutics Inc. $OTLK	8/31/2023	$5.00 → $1.00	Buy → Neutral	H.C. Wainwright
Outlook Therapeutics Inc. $OTLK	8/31/2023		Buy → Neutral	Chardan Capital Markets
Outlook Therapeutics Inc. $OTLK	8/30/2023		Overweight → Equal Weight	CapitalOne

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

Chat with this insight

Recent Analyst Ratings for $AEZS$AIM$AMAO$AREC

$AEZS$AIM$AMAO$AREC Financials

Live finance-specific insights

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

$AEZS$AIM$AMAO$AREC Press Releases

Fastest customizable press release news feed in the world

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

American Resources Corporation's ReElement Technologies and POSCO International Come Together to Develop a Sustainable Rare Earth Element and Magnet Supply Chain

SurgePays Establishes Strategic Agreement with AT&T

$AEZS$AIM$AMAO$AREC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Moleculin Biotech Inc.

Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by enVVeno Medical Corporation

$AEZS$AIM$AMAO$AREC Leadership Updates

Live Leadership Updates

SurgePays Establishes Strategic Agreement with AT&T

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

$AEZS$AIM$AMAO$AREC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CEO & President Equels Thomas K bought $16,915 worth of shares (85,000 units at $0.20), increasing direct ownership by 5% to 1,637,968 units (SEC Form 4)

Director Appelrouth Stewart bought $15,817 worth of shares (81,953 units at $0.19), increasing direct ownership by 34% to 321,752 units (SEC Form 4)

Director Schurfeld Richard Earl bought $5,593 worth of Shares of Common Stock (3,500 units at $1.60), increasing direct ownership by 8% to 47,501 units (SEC Form 4)

$AEZS$AIM$AMAO$AREC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CEO & President Equels Thomas K bought $16,915 worth of shares (85,000 units at $0.20), increasing direct ownership by 5% to 1,637,968 units (SEC Form 4)

Director Appelrouth Stewart bought $15,817 worth of shares (81,953 units at $0.19), increasing direct ownership by 34% to 321,752 units (SEC Form 4)

Director Schurfeld Richard Earl bought $5,593 worth of Shares of Common Stock (3,500 units at $1.60), increasing direct ownership by 8% to 47,501 units (SEC Form 4)

$AEZS$AIM$AMAO$AREC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Outlook Therapeutics upgraded by BTIG Research with a new price target

SurgePays downgraded by Maxim Group

Outlook Therapeutics upgraded by Chardan Capital Markets with a new price target

$AEZS$AIM$AMAO$AREC Market Insights

Live Market Insights

AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model

SurgePays Announces ClearLine's Launch Of POS Marketing Solution Integrated With Clover And PAX Devices; To Debut At RSPA RetailNOW Conference In Las Vegas

Cyclo Therapeutics Has Been Granted European Patent Number EP3873604 Titled "METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN"

$AEZS$AIM$AMAO$AREC SEC Filings

Amendment: SEC Form S-1/A filed by Palisade Bio Inc.

SEC Form DEF 14A filed by enVVeno Medical Corporation

SEC Form 10-Q filed by American Resources Corporation

Recent Analyst Ratings for
$AEZS
$AIM
$AMAO
$AREC

$AEZS
$AIM
$AMAO
$AREC
Financials

$AEZS
$AIM
$AMAO
$AREC
Press Releases

$AEZS
$AIM
$AMAO
$AREC
Large Ownership Changes

$AEZS
$AIM
$AMAO
$AREC
Leadership Updates

$AEZS
$AIM
$AMAO
$AREC
Insider Purchases

$AEZS
$AIM
$AMAO
$AREC
Insider Trading

$AEZS
$AIM
$AMAO
$AREC
Analyst Ratings

$AEZS
$AIM
$AMAO
$AREC
Market Insights

$AEZS
$AIM
$AMAO
$AREC
SEC Filings